Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| United States Department of Defense | FED |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the pharmacodynamics effects of itraconazole in early-stage non-small cell lung cancer.
This is a phase 0 clinical trial. While clinical data including safety will be recorded, the principal outcomes are pharmacodynamic endpoints. Specifically, the investigators seek to identify: (1) effects of itraconazole on tumor angiogenesis, (2) effects of itraconazole on the Hh pathway, (3) biomarker predictors of these effects, (4) the correlation between itraconazole pharmacokinetics and these effects, (5) the correlation between different biomarkers.
Up to 15 eligible patients with previously diagnosed or suspected NSCLC planned for resection will undergo a study-specific core needle biopsy, imaging (dynamic contrast enhanced [DCE]-, diffusion weighted imaging [DWI]-, and arterial spin labeling [ASL] magnetic resonance imaging [MRI]), skin punch biopsy, and collection of peripheral blood. Subjects will then receive itraconazole 600 mg PO daily for 7-10 days, following which they will undergo repeat imaging, skin biopsy, and blood collection. Subsequently they will undergo surgical resection. Due to the safety profile of itraconazole when used as an antifungal agent , all histologic subtypes of NSCLC will be eligible for the trial. The itraconazole dose of 600 mg, higher than an anti-angiogenic dose, has been shown to inhibit the Hedgehog (Hh) pathway.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Itraconazole | Other | 600 mg twice daily for 10-14 days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Itraconazole | Drug | Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, "Post-treatment" assessments will include a skin biopsy, blood draw for the PK (pharmacokinetics) analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Tumor Tissue Microvessel Density [MVD] From Baseline | Images of DAPI (4',6-Diamidino-2-Phenylindole) , CD31 (cluster of differentiation 31 ), and CD34 (cluster of differentiation 34) were taken from the same field of view and then merged. | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in HIF1α From Baseline | A commercially available kit will be used to measure HIF1α levels. | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Change in VEGFR2 From Baseline |
Not provided
Inclusion Criteria:
Histologically or cytologically proven NSCLC planned for surgical resection. All NSCLC histologic subtypes are eligible. Alternatively, patients in whom a diagnosis of NSCLC is highly suspected based on history and imaging studies and who are, therefore, scheduled for diagnostic biopsy and/or surgical resection will also be eligible for screening, enrollment, and study treatment if they meet all additional eligibility criteria. In the event that biopsies do not confirm NSCLC, such patients will be removed from study but monitored for any adverse events resulting from study participation.
No prior therapy but planned for surgical resection
Age ≥ 18 years.
ECOG (Eastern Cooperative Oncology Group) 0-2 performance status
Adequate organ function as defined below:
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
6.1 A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
Ability to understand and willingness to sign a written informed consent.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lorraine Pelosof, M.D. | University of Texas Southwestern Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UT Southwestern Medical Center | Dallas | Texas | 75390 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Itraconazole | 600 mg twice daily for 10-14 days Itraconazole: Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, "Post-treatment" assessments will include a skin biopsy, blood draw for the PK analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Itraconazole | 600 mg twice daily for 10-14 days Itraconazole: Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, "Post-treatment" assessments will include a skin biopsy, blood draw for the PK analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Changes in Tumor Tissue Microvessel Density [MVD] From Baseline | Images of DAPI (4',6-Diamidino-2-Phenylindole) , CD31 (cluster of differentiation 31 ), and CD34 (cluster of differentiation 34) were taken from the same field of view and then merged. | Posted | Mean | Standard Deviation | Percent area fraction | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
10 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Itraconazole | 600 mg twice daily for 10-14 days Itraconazole: Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, "Post-treatment" assessments will include a skin biopsy, blood draw for the PK analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. David Gerber | UT Southwestern Medical Center | 214-648-4180 | David.Gerber@UTSouthwestern.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | May 1, 2017 | Aug 13, 2020 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D017964 | Itraconazole |
| ID | Term |
|---|---|
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
A commercially available kit will be used to measure VEGFR2 levels.
| Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Change in Phospho-VEGFR2 From Baseline | A commercially available kit will be used to measure Phospho-VEGFR2 levels. | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Mean Percent Change in Other Plasma Cytokine From Baseline to Post-Treatment | The following plasma cytokines were measured using a commercially available kit. | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Mean Percent Change in Angiogenic Cytokines From Baseline | A commercially available kit will be used to measure Angiogenic Cytokines levels. | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Changes in Perfusion (Ktrans) | DCE (dynamic contrast enhanced ) MRI is an established technology to assess microvessel density (MVD) and tumor capillary permeability. | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Number of Participants With Tumor SMO (Smoothened) Gene Mutations, GLI2 and CCND1 Copy Number, PI3K-mTOR Pathway Activation | phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (PI3K-mTOR pathway ) | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Change in Tumor Tissue GLI1, SHH and PTCH1 Levels From Baseline | This can be measured by analyzing frozen-treated tumor tissue for GLI1 (glioma-associated oncogene ) and PTCH1(patched-1) mRNA (Messenger Ribonucleic Acid) by qPCR. | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Change in Skin Biopsy GLI1 Levels From Baseline | We analyzed serial skin biopsies for GLI1 mRNA by qPCR (quantitative polymerase chain reaction). | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Change in Skin Biopsy SHH Levels From Baseline | We analyzed serial skin biopsies for SHH (Sonic Hedgehog )levels mRNA by qPCR. | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Change in Skin Biopsy PTCH1 Levels From Baseline | We analyzed serial skin biopsies for PTCH1 mRNA by qPCR. | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Number of Participants With Tumor Cell Proliferation/Apoptosis | Tumor proliferation and apoptosis will be assessed by tumor Ki67 and cleaved caspase 3 levels | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Itraconazole Levels in Post-treatment Serum | Itraconazole levels assessed by post-treatment serum | Post Treatment (after 7-10 days of itraconazole bid) |
| Itraconazole Levels in Tumor Tissue | Itraconazole levels assessed by tumor tissue | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| Itraconazole Levels in Skin Biopsy | Itraconazole levels assessed by skin biopsy | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Histology | Count of Participants | Participants |
|
| Smoking History | Count of Participants | Participants |
|
|
|
| Secondary | Change in HIF1α From Baseline | A commercially available kit will be used to measure HIF1α levels. | We did not collect this data as we did not perform this assay. | Posted | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
| Secondary | Change in VEGFR2 From Baseline | A commercially available kit will be used to measure VEGFR2 levels. | We did not collect this data as we did not perform this assay. | Posted | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
| Secondary | Change in Phospho-VEGFR2 From Baseline | A commercially available kit will be used to measure Phospho-VEGFR2 levels. | We did not collect this data as we did not perform this assay. | Posted | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
| Secondary | Mean Percent Change in Other Plasma Cytokine From Baseline to Post-Treatment | The following plasma cytokines were measured using a commercially available kit. | The 2 missing cases not included in this analysis here were due to inability to collect the follow-up sample. | Posted | Mean | Standard Error | Percent change | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
|
| Secondary | Mean Percent Change in Angiogenic Cytokines From Baseline | A commercially available kit will be used to measure Angiogenic Cytokines levels. | The 2 missing cases not included in this analysis here were due to inability to collect the follow-up sample. | Posted | Mean | Standard Error | Percent change | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
|
| Secondary | Changes in Perfusion (Ktrans) | DCE (dynamic contrast enhanced ) MRI is an established technology to assess microvessel density (MVD) and tumor capillary permeability. | Reasons that enrolled patients did not complete paired research MRI scans included presence of metal implants, inadequate renal function, and patient preference | Posted | Mean | Standard Deviation | min-1 | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
|
| Secondary | Number of Participants With Tumor SMO (Smoothened) Gene Mutations, GLI2 and CCND1 Copy Number, PI3K-mTOR Pathway Activation | phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (PI3K-mTOR pathway ) | This was initially planned and did not collect data for this and did not assess. | Posted | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
| Secondary | Change in Tumor Tissue GLI1, SHH and PTCH1 Levels From Baseline | This can be measured by analyzing frozen-treated tumor tissue for GLI1 (glioma-associated oncogene ) and PTCH1(patched-1) mRNA (Messenger Ribonucleic Acid) by qPCR. | The lab tests were not feasible with tumor tissues as they were not enough to conduct these tests. | Posted | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
| Secondary | Change in Skin Biopsy GLI1 Levels From Baseline | We analyzed serial skin biopsies for GLI1 mRNA by qPCR (quantitative polymerase chain reaction). | Participant with missing data were excluded from the analysis | Posted | Mean | Standard Deviation | relative units | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
|
| Secondary | Change in Skin Biopsy SHH Levels From Baseline | We analyzed serial skin biopsies for SHH (Sonic Hedgehog )levels mRNA by qPCR. | SHH levels were not measured. | Posted | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
| Secondary | Change in Skin Biopsy PTCH1 Levels From Baseline | We analyzed serial skin biopsies for PTCH1 mRNA by qPCR. | Participant with missing data were excluded from the analysis | Posted | Mean | Standard Deviation | relative units | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
|
| Secondary | Number of Participants With Tumor Cell Proliferation/Apoptosis | Tumor proliferation and apoptosis will be assessed by tumor Ki67 and cleaved caspase 3 levels | This was not feasible with the available tissue samples and hence data not collected. | Posted | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
| Secondary | Itraconazole Levels in Post-treatment Serum | Itraconazole levels assessed by post-treatment serum | The 2 missing cases not included in this analysis here were due to inability to collect the follow-up sample. | Posted | Mean | Standard Deviation | ng/mL | Post Treatment (after 7-10 days of itraconazole bid) |
|
|
|
| Secondary | Itraconazole Levels in Tumor Tissue | Itraconazole levels assessed by tumor tissue | The 4 missing cases not included in this analysis here were due to inability to collect the follow-up sample. | Posted | Mean | Standard Deviation | ng/g | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
|
| Secondary | Itraconazole Levels in Skin Biopsy | Itraconazole levels assessed by skin biopsy | We have not measured itraconazole level in skin biopsy. | Posted | Baseline and Post Treatment (after 7-10 days of itraconazole bid) |
|
|
| 0 |
| 13 |
| 0 |
| 13 |
| 2 |
| 13 |
| Heartburn | Gastrointestinal disorders | Non-systematic Assessment |
|
| Non-Cardiac chest pain | General disorders | Non-systematic Assessment |
|
Not provided
Not provided
Not provided
| D013899 |
| Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D010879 |
| Piperazines |
| Title | Measurements |
|---|---|
|
| IL-4 |
|
| IL-5 |
|
| IL-6 |
|
| IL-7 |
|
| IL-9 |
|
| IL-10 |
|
| IL-12 |
|
| IL-13 |
|
| IL-15 |
|
| IL-17 |
|
| IP-10 |
|
| MCP-1 |
|
| MIP-1a |
|
| MIP-1b |
|
| RANTES |
|
| TNF-a |
|
| IFN-g |
|
| Eotaxin |
|
| G-CSF |
|
| GM-CSF |
|
| Title | Measurements |
|---|---|
|
| FGF-b |
|